Free account + included starter software — credential review typically takes 1–2 business days. See how it works
NDC 47335-0188-88

CARBIDOPA AND LEVODOPA 25 mg/1, 250 mg/1 TABLET, ORALLY DISINTEGRATING

Available — 2-Day Shipping
NDC
47335-0188-88
Generic Name
CARBIDOPA AND LEVODOPA
Brand Name
CARBIDOPA AND LEVODOPA
Strength
25 mg/1, 250 mg/1
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Package Size
Labeler
Sun Pharmaceutical Industries, Inc.

FDA Drug Information

Indications & Usage

INDICATIONS AND USAGE Carbidopa and levodopa orally disintegrating tablets are indicated in the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson’s disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa orally disintegrating tablets. This is most likely due…

Important Warnings

WARNINGS When carbidopa and levodopa orally disintegrating tablet is to be given to patients who are being treated with levodopa, levodopa must be discontinued at least twelve hours before therapy with carbidopa and levodopa orally disintegrating tablet is started. In order to reduce adverse reactions, it is necessary to individualize therapy. See DOSAGE AND ADMINISTRATION section before initiatin…

Source: FDA. For professional use only. Not a substitute for prescribing information.

Order NDC 47335-0188-88 at Wholesale

Create a free Premier Pharma account to unlock live wholesale pricing and place orders with same-day fulfillment and full DSCSA T2 documentation (TI + TS).